Reading a Peptide HPLC Trace — A 5-Minute Field Guide for Bench Scientists. Read our briefing →
Reading a peptide HPLC trace — a field guide. Read →
On reading HPLC traces. Read →
Long-acting amylin analog · metabolic research peptide
Overview
Cagrilintide is a long-acting synthetic analog of amylin, the pancreatic peptide hormone co-secreted with insulin that contributes to satiety and gastric-emptying regulation. It is most studied in combination with Semaglutide (the co-formulation referenced in the literature as CagriSema), where the amylin and GLP-1 pathways are investigated for additive metabolic effects. As an investigational compound it is not an approved finished drug; the material supplied here is a research reagent only. Lyochem supplies Cagrilintide as a lyophilized powder characterized lot-by-lot: RP-HPLC purity (gradient method, UV 214 nm), ESI-MS for identity, sequence confirmation by LC-MS/MS, counter-ion content, and water content by Karl Fischer. Sequence verification by tandem MS is available on request and recommended at first-time qualification. For labs studying the amylin + GLP-1 combination, Lyochem supplies Cagrilintide and Semaglutide as separate characterized lots rather than a pre-mixed blend, so each can be confirmed against its own analytical packet before the buyer prepares the combination in-protocol. Fills run mg-scale; this is reference-grade research material, distinct from compounding-scale API supply.
Who buys this, and why
GLP-1 and metabolic-peptide buyers run incretin-pathway, body-composition, glucose-regulation, and energy-expenditure studies. Because the receptor pharmacology is sequence-sensitive, qualifying a new source means confirming identity within 0.5 Da of theoretical by ESI-MS, sequence verification by tandem MS on the first lot, and lot-to-lot consistency for reproducible metabolic research. Lyochem supplies this class reference-grade and mg-scale — distinct from compounding-grade (g/kg) API supply.
Primary buyer fit: academic laboratories at universities and government research institutes and biotech and pharmaceutical R&D groups running preclinical discovery.
Specifications
Documentation available on request
Regulatory note
Investigational compound; not approved as a finished drug in any jurisdiction. Sold for Research Use Only under the receiving laboratory's institutional and jurisdictional regulations — not a finished dosage form and not labelled for human administration. Buyers are responsible for institutional biosafety review and verifying import eligibility in the destination market.
Frequently asked questions
Cagrilintide is a long-acting synthetic analog of amylin, a pancreatic peptide co-secreted with insulin that contributes to satiety signalling and gastric-emptying regulation. The native hormone has a very short half-life; Cagrilintide is engineered for extended action, which is why it is used as the amylin-pathway reference in metabolic research. CAS is 1415456-99-3; identity is confirmed by ESI-MS against the theoretical mass for the supplied form on every lot COA.
Cagrilintide (amylin pathway) and Semaglutide (GLP-1 pathway) act through distinct receptors, and the combination referenced in the literature as CagriSema is studied for additive metabolic effects beyond either pathway alone. The amylin arm contributes satiety and gastric-emptying effects that complement the incretin mechanism, which is the rationale for the combination being a frequent subject in incretin-plus-amylin pharmacology studies.
No. Lyochem supplies Cagrilintide and Semaglutide as separate characterized lots, each with its own analytical packet, rather than a pre-mixed blend. This lets a lab confirm the identity and purity of each component independently before preparing the combination in-protocol, which is the methodologically cleaner approach for research; a pre-mixed blend obscures the per-component analytical data that a citable methods section needs.
Related peptides